In a major relief for patients suffering from mucormycosis (black fungus), the Maharashtra government on Friday announced a cap on the treatment rates charged by private hospitals.
Chief Minister Uddhav Thackeray has approved a proposal by the Health Ministry fixing the charges to be levied by all private hospitals, till July 31, to make it affordable for the common man.
The development comes a fortnight after the state government issued an order on May 18 to provide free treatment, including medicines, beds, etc, to mucormycosis patients under the Mahatma Jyotiba Jan Arogya Yojana and the Pradhan Mantri Jan Arogya Yojana, at 130 pre-determined hospitals, besides empaneling another 1000 hospitals.
There are around 2,000 black fungus cases in the state currently with more than 150 deaths recorded till date, which are considered the highest in the country, according to officials.
The order issued by the state government classifies areas in thee categories, A, B and C categories and different rates have been fixed for the three.
In the A class, under which Mumbai, Pune and Nagpur fall, the daily treatment rate for ward patients has been capped at Rs4,000. The rates for intensive care unit (ICU) without ventilator and ICU with ventilator support have been fixed at Rs7,500 and Rs9,000, respectively
For the B category, comprising Nasik, Amravati, Aurangabad, Bhiwandi, Solapur, Kolhapur, Vasai Virar, Malegaon, Nanded and Sangli, daily rate for ward treatment has been fixed at Rs3,000. The rates for ICU with and without ventilator support have been capped at Rs5,500 and Rs6,700, respectively.
In the remaining areas in the state, which are classified under C class, the rates have been capped at Rs2,400 for wards, Rs4,500 for ICU without ventilator and Rs5,400 for ICU with ventilator support.
These rates do not cover costs of high-end drugs or diagnostic procedures such as CT scans and MRI, the order says. The order has also capped rates for surgical procedures, with separate charges applicable for A, B and C categories.
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.